18.07
-0.39 (-2.11%)
| Previous Close | 18.46 |
| Open | 18.70 |
| Volume | 1,370,373 |
| Avg. Volume (3M) | 1,984,333 |
| Market Cap | 5,770,317,824 |
| Price / Earnings (TTM) | 38.45 |
| Price / Sales | 1.88 |
| Price / Book | 172.86 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2026 |
| Profit Margin | -0.46% |
| Operating Margin (TTM) | 14.51% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Quarterly Earnings Growth (YOY) | -49.70% |
| Current Ratio (MRQ) | 1.40 |
| Operating Cash Flow (TTM) | 306.92 M |
| Levered Free Cash Flow (TTM) | 311.48 M |
| Return on Assets (TTM) | 6.67% |
| Return on Equity (TTM) | -881.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Amneal Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.75 |
|
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 46.75% |
| % Held by Institutions | 43.76% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BUCHI J KEVIN | - | - | 0 | 0 |
| DALY JASON B. | - | 17.38 | -216,613 | -3,821,682 |
| PATEL CHINTU | 17.88 | - | 6,381,734 | 114,105,404 |
| PATEL CHIRAG K. | 17.88 | - | 6,381,734 | 114,105,404 |
| PATEL GAUTAM | 17.88 | - | 283,632 | 5,071,340 |
| PATEL TUSHAR BHIKHUBHAI | 17.88 | - | 12,763,469 | 228,210,826 |
| SHAH NIKITA | - | 17.66 | -146,403 | -2,585,477 |
| Aggregate Net Quantity | 25,447,553 | |||
| Aggregate Net Value ($) | 455,085,814 | |||
| Aggregate Avg. Buy ($) | 17.88 | |||
| Aggregate Avg. Sell ($) | 17.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DALY JASON B. | Officer | 12 Aug 2026 | Sell (-) | 210,000 | 17.66 | 3,708,600 |
| SHAH NIKITA | Officer | 12 Aug 2026 | Sell (-) | 146,403 | 17.66 | 2,585,477 |
| BUCHI J KEVIN | Director | 11 Aug 2026 | Option execute | 168,573 | - | - |
| DALY JASON B. | Officer | 11 Aug 2026 | Sell (-) | 6,613 | 17.10 | 113,082 |
| PATEL CHIRAG K. | Officer | 10 Aug 2026 | Acquired (+) | 6,381,734 | 17.88 | 114,105,404 |
| PATEL GAUTAM | Director | 10 Aug 2026 | Acquired (+) | 283,632 | 17.88 | 5,071,340 |
| PATEL CHINTU | Officer | 10 Aug 2026 | Acquired (+) | 6,381,734 | 17.88 | 114,105,404 |
| PATEL TUSHAR BHIKHUBHAI | 10 Aug 2026 | Acquired (+) | 12,763,469 | 17.88 | 228,210,826 |
| Date | Type | Details |
|---|---|---|
| 29 Jun 2026 | CNBC | Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |